Skip to main content

Advertisement

Table 2 p53 , CDKN1A and MDM2 sequence analysis

From: In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients

Donor ID (passages analyzed) TP53 CDKN1A p21 MDM2 SNP 309
refSNP Exon Status refSNP Exon Status refSNP Status
MSC-SAR 1 (p4/p10) rs1642785 2 HO      
rs17878362 3 HO
rs1042522 4 HO
MSC-SAR 2 (p4/p10) rs1642785 2 HE     rs2279745 HE
rs17878362 3 HO
rs1042522 4 HE
MSC-SAR 3 (p4/p6) rs1642785 2 HO      
rs17878362 3 HO
rs1042522 4 HO
MSC-SAR 4 (p4/p10) rs1642785 2 HE rs1059234 3 HE   
rs17878362 3 HE
rs1800370 4 HE
rs1042522 4 HE
MSC-SAR 5 (p4/p10) rs1642785 2 HE     rs2279745 HE
rs17878362 3 HO
rs1042522 4 HE
rs12947788 7 HE
rs12951053 7 HE
MSC-SAR 6 (p4/p10) rs17878362 3 HO     rs2279745 HE
rs12947788 7 HE
rs12951053 7 HE
MSC-CTRL 1 (p4/p10) rs1642785 2 HO      
rs17878362 3 HO
rs1042522 4 HO
MSC-CTRL 2 (p3/p10) rs1642785 2 HO      
rs17878362 3 HO
rs1042522 4 HO
  1. Sequence analysis of DNA samples from MSC-SAR and MSC-CTRL patients was performed at the indicated culture passages. PCR amplification was performed on the 11 exons of TP53, the 3 exons of CDKN1A along with exon–intron junctions, and on the SNP309 (rs2279744) in MDM2. P, passages; HO, homozygous; HE, heterozygous.